The Leigh Syndrome International Consortium is a global patient-driven research network. It aims to accelerate new treatments and therapies.
The Consortium is a unique partnership between 5 leading mito advocacy organisations:
- Lily Foundation, UK
- Mitocon ODV, Italy
- Mito Foundation, Australia
- United Mitochondrial Disease Foundation (UMDF), USA
- People Against Leigh Syndrome (PALS), USA.
Together, they have committed over $1 million USD to this multi-year project.
The consortium funds research to:
- improve diagnosis
- support treatment development
- strengthen care for people with Leigh Syndrome.
Call for Partners: Join the Leigh Syndrome International Consortium
We are seeking advocacy organisations, foundations, and aligned partners to join the Consortium from 2027–2030.
As a partner, you will help shape research, strengthen global data, and support future treatment development.
This next phase focuses on:
- sustaining and expanding the Natural History Study
- enabling future research and therapy development.
Key details:
- Partnership period: 2027–2030
- Minimum contribution: USD $100,000
- Total funding target: USD $500,000
- Expression of Interest deadline: 30 April 2026
If your organisation is ready to collaborate, we encourage you to apply.
PARTNERS
